140 related articles for article (PubMed ID: 36040613)
1. Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.
Hernández-Mitre MP; Tong SYC; Denholm JT; Dore GJ; Bowen AC; Lewin SR; Venkatesh B; Hills TE; McQuilten Z; Paterson DL; Morpeth SC; Roberts JA
Clin Pharmacokinet; 2022 Oct; 61(10):1331-1343. PubMed ID: 36040613
[TBL] [Abstract][Full Text] [Related]
2. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
4. Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study.
Soma T; Fujii K; Yoshifuji A; Maruki T; Itoh K; Taniyama D; Kikuchi T; Hasegawa N; Nakamura M
Jpn J Infect Dis; 2022 Sep; 75(5):484-489. PubMed ID: 35491224
[TBL] [Abstract][Full Text] [Related]
5. In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity.
Fujimoto KJ; Hobbs DCF; Umeda M; Nagata A; Yamaguchi R; Sato Y; Sato A; Ohmatsu K; Ooi T; Yanai T; Kimura H; Murata T
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215982
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate.
Hernández-Mitre MP; Morpeth SC; Venkatesh B; Hills TE; Davis J; Mahar RK; McPhee G; Jones M; Totterdell J; Tong SYC; Roberts JA
Clin Microbiol Infect; 2024 Jun; 30(6):743-754. PubMed ID: 38331253
[TBL] [Abstract][Full Text] [Related]
7. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
[TBL] [Abstract][Full Text] [Related]
8. The Effectiveness and Safety of Nafamostat Mesylate in the Treatment of COVID-19: a Meta-Analysis.
Wei M; Li T; Liu S; Wang Y; Tran C; Ao G
Jpn J Infect Dis; 2024 May; 77(3):182-186. PubMed ID: 38296543
[TBL] [Abstract][Full Text] [Related]
9. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
[TBL] [Abstract][Full Text] [Related]
10. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics.
Quinn TM; Gaughan EE; Bruce A; Antonelli J; O'Connor R; Li F; McNamara S; Koch O; MacKintosh C; Dockrell D; Walsh T; Blyth KG; Church C; Schwarze J; Boz C; Valanciute A; Burgess M; Emanuel P; Mills B; Rinaldi G; Hardisty G; Mills R; Findlay EG; Jabbal S; Duncan A; Plant S; Marshall ADL; Young I; Russell K; Scholefield E; Nimmo AF; Nazarov IB; Churchill GC; McCullagh JSO; Ebrahimi KH; Ferrett C; Templeton K; Rannard S; Owen A; Moore A; Finlayson K; Shankar-Hari M; Norrie J; Parker RA; Akram AR; Anthony DC; Dear JW; Hirani N; Dhaliwal K
EBioMedicine; 2022 Feb; 76():103856. PubMed ID: 35152152
[TBL] [Abstract][Full Text] [Related]
11. Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.
Iwasaka S; Shono Y; Tokuda K; Nakashima K; Yamamoto Y; Maki J; Nagasaki Y; Shimono N; Akahoshi T; Taguchi T
J Infect Chemother; 2020 Dec; 26(12):1319-1323. PubMed ID: 32893123
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
13. RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia.
Seccia TM; Shagjaa T; Morpurgo M; Caroccia B; Sanga V; Faoro S; Venturini F; Iadicicco G; Lococo S; Mazzitelli M; Farnia F; Fioretto P; Kobayashi Y; Gregori D; Rossi GP
J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892756
[TBL] [Abstract][Full Text] [Related]
14. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.
Mantzourani C; Vasilakaki S; Gerogianni VE; Kokotos G
Expert Opin Drug Discov; 2022 Mar; 17(3):231-246. PubMed ID: 35072549
[TBL] [Abstract][Full Text] [Related]
15. Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies.
M P; Reddy GJ; Hema K; Dodoala S; Koganti B
Eur J Pharmacol; 2021 Jan; 890():173688. PubMed ID: 33130280
[TBL] [Abstract][Full Text] [Related]
16. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
[TBL] [Abstract][Full Text] [Related]
17. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
Breining P; Frølund AL; Højen JF; Gunst JD; Staerke NB; Saedder E; Cases-Thomas M; Little P; Nielsen LP; Søgaard OS; Kjolby M
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):204-212. PubMed ID: 33176395
[TBL] [Abstract][Full Text] [Related]
18. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.
Hoffmann M; Schroeder S; Kleine-Weber H; Müller MA; Drosten C; Pöhlmann S
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32312781
[No Abstract] [Full Text] [Related]
19. Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2.
Ianevski A; Yao R; Lysvand H; Grødeland G; Legrand N; Oksenych V; Zusinaite E; Tenson T; Bjørås M; Kainov DE
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578348
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.
Ko M; Jeon S; Ryu WS; Kim S
J Med Virol; 2021 Mar; 93(3):1403-1408. PubMed ID: 32767684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]